Skip to content
The Nexus
DossierENTITY

National Priority Voucher (CNPV) pilot program

Coverage of National Priority Voucher (CNPV) pilot program in the Nexus archive.

Earliest in view: Apr 24 · 17:47 UTCMost recent: Apr 24 · 17:47 UTC
Co-mentioned in this coverage
Food and Drug Administrationorganization1Otarmeni (lunsotogene parvec-cwha)topic1OTOF genetopic1FDA Commissioner Marty Makaryperson1The New England Journal of Medicineorganization1Otoferlintopic1Cochleatopic1
Recent coverage
  • HEALTHApr 24 · 17:47 UTCFOX NEWS
    First-ever gene therapy for hearing loss gets FDA approval: 'Groundbreaking'

    The FDA approved Otarmeni, the first dual adeno-associated virus (AAV) gene therapy for genetic hearing loss linked to the OTOF gene. The treatment, administered surgically to the inner ear, improved hearing in some patients with OTOF-related deafness, marking the first disease-modifying therapy for this condition.